Testosterone Research News for Healthcare Professionals

Testosterone treatment and sleep disorders

menshealthcare@bayerhealthcare.com — Thu, 02 May 2013 13:00:00 +0100

Millions of men have received testosterone therapy over the past several decades, but only a few studies have addressed the possible link between testosterone treatment and obstructive sleep apnea (OSA). Despite the small number of patients studied, publications have generally cautioned clinicians about the possible cause or aggravation of OSA by testosterone therapy. A review of the literature by Hanafy in 2007 evaluated the scientific data behind these cautionary statements and found a lack of consistent findings from case studies and different patient groups and that the link between testosterone and OSA was weak. Further well designed studies in this area were recommended from this review.

Read more

Testosterone may be beneficial for metabolic syndrome-associated prostate inflammation

menshealthcare@bayerhealthcare.com — Mon, 22 Apr 2013 13:00:00 +0100

A recent non-systematic literature review evaluated studies providing evidence of the role of metabolic syndrome in the development and progression of benign prostatic hyperplasia (BPH) and prostate cancer (PCa). In this evaluation the authors considered relevant articles (in both humans and animals) published between 1995 and September 2011 that were identified using PubMed. The review highlighted several observational studies which showed that metabolic syndrome is associated with an increased risk of lower urinary tract symptoms (LUTS) and BPH. Although the molecular pathways of metabolic syndrome as related to the prostate remain incompletely characterized, the cumulative evidence suggests an association between metabolic syndrome and its mediators and the development of BPH and PCa. An understanding of the metabolic syndrome pathway may identify new therapeutic targets and expose novel strategies to reduce the risk of benign and malignant prostate tumors.

Read more

Testosterone for the treatment of obesity in hypogonadal men

menshealthcare@bayerhealthcare.com — Wed, 27 Mar 2013 13:00:00 +0100

A recent review of the PubMed literature evaluated studies reporting data on the role of testosterone in counteracting obesity and its associated complications in men with testosterone deficiency (hypogonadism).1 The role of testosterone in this regard was summarized from three perspectives: i) evidence from epidemiological and observational studies; ii) evidence from androgen deprivation therapy (ADT), mainly in men undergoing treatment for prostate cancer (PCa); and iii) evidence from testosterone treatment of men with testosterone deficiency.

Read more

Long-acting testosterone undecanoate is well tolerated in men with hypogonadism in daily clinical practice

menshealthcare@bayerhealthcare.com — Thu, 28 Feb 2013 13:00:00 +0100

Changes in the worldwide diagnosis and treatment of testosterone deficiency between 2006 and 2010

menshealthcare@bayerhealthcare.com — Mon, 19 Nov 2012 17:00:00 +0100

This physician-based survey investigated the diagnosis and treatment of testosterone deficiency (hypogonadism) in various parts of the world in 2010. The study, conducted in Germany, Spain, the United Kingdom, Brazil and Saudi Arabia between April and May 2010, involved 353 physicians (229 urologists, 84 endocrinologists and 40 primary care physicians) who were interviewed to address the following issues (1) the reasons to use/not use testosterone in patients who have testosterone deficiency (2) the role of safety and other concerns in the decision to not provide testosterone treatment and (3) to evaluate the actual use of testosterone preparations for the treatment of erectile dysfunction. The results of this survey were compared with a previous survey conducted in Germany, Spain, the United Kingdom, Brazil and South Korea by the same investigators in 2006 to determine if any significant changes in clinical practice have occurred over the last 4 years.

Read more

Efficacy and safety of long-acting testosterone undecanoate in men with hypogonadism in daily clinical practice

menshealthcare@bayerhealthcare.com — Fri, 26 Oct 2012 13:00:00 +0100

This prospective, observational, post-authorization surveillance study investigated the safety and efficacy of intramuscular injections of testosterone undecanoate (TU) in men with testosterone deficiency syndrome (hypogonadism) in a clinical practice setting. The study, conducted in 23 countries throughout Europe, Asia, Latin America and Australia, enrolled 1493 men (mean age 49.2 ± 13.9 years) with a diagnosis of primary or secondary testosterone deficiency syndrome (serum total testosterone 8–12 nmol/L for newly diagnosed treatment-naïve patients). The men received up to five injections of TU during an observation period of 9–12 months. Between the first and second injections of the agent there was an interval of 6–10 weeks, and subsequent injections were given at intervals of 12 ± 2 weeks.

The study aimed to assess treatment outcomes of male patients with testosterone deficiency syndrome who received TU under ‘real-life’ conditions, and to assess the treatment continuation rate in such patients and further confirm the safety profile of TU. Parameters of erectile function, libido, vigor/vitality, mood and ability to concentrate were assessed by physician interview using items and five-point Likert scales. Certain physical and circulatory parameters, as well as other laboratory parameters, were also measured at each injection visit.

Read more

Effects of long-acting testosterone undecanoate on quality of life in Asian men with testosterone deficiency syndrome

menshealthcare@bayerhealthcare.com — Fri, 05 Oct 2012 17:00:00 +0100

This 12-month double blind, randomized controlled study investigated the effects of intramuscular injections of testosterone undecanoate on overall quality of life (QoL) in men with testosterone deficiency syndrome (hypogonadism). The study, conducted in Malaysia, enrolled 120 men aged ≥40 years with a diagnosis of testosterone deficiency syndrome (serum total testosterone <12 nmol/L (346 ng/dL) and total Aging Males’ Symptoms (AMS) scores ≥27). Men received placebo or 1000 mg testosterone undecanoate by intramuscular injection at weeks 0, 6, 18, 30 and 42.

The primary analysis of the study, treatment effects using the AMS scale, has been published previously and was reported in the Research News on this website on 25 July 2012. This paper reported the secondary analysis of QoL changes, measured by the Medical Outcomes Study Short-Form-12 (SF-12) scale at baseline, week 30 and week 48. SF-12 is a self-administered validated tool designed to measure general health-related QoL. It measures 8 domains of QoL and has 2 composite scores for physical and mental health.

Read more

Effects of long-term long-acting testosterone undecanoate on bone mineral density in men with late-onset hypogonadism and metabolic syndrome

menshealthcare@bayerhealthcare.com — Mon, 10 Sep 2012 15:00:00 +0100

This study evaluated the long-term effects of testosterone replacement therapy (TRT) on the bone mineral density (BMD) of obese patients with metabolic syndrome (MetS) and/or type 2 diabetes mellitus (T2DM) and late-onset hypogonadism. Sixty Caucasian men aged 45–65 (mean 57) years with low serum testosterone (>11 nmol/L [320 ng/dL]) or calculated free testosterone >74 pg/mL (255 pmol/L) were enrolled. Treatment consisted of intramuscular testosterone undecanoate 4 times/year for 36 months (20 men). Twenty age-matched hypogonadal men with MetS in whom TRT was contraindicated were used as controls.

The remaining 20 men in the TRT group did not complete the study (and were not included in the analysis) because of mild and transient erythrocytosis (4 patients), increased prostate-specific antigen levels (1), personal reasons (6) or dropped out before completing the 36 months of observation (9). At baseline, mean lumbar BMD was 0.891±0.097 g/cm², femoral BMD was 0.847±0.117 g/cm², lumbar T-score was –1.6±0.9 and femoral neck T-score was 0.9±0.8, indicating that patients had mild osteopenia.

Retrospective observational study finds hypogonadism prevalent in men with sexual dysfunction and related to a range of chronic illnesses

menshealthcare@bayerhealthcare.com — Tue, 21 Aug 2012 19:00:00 +0100

This retrospective, observational study evaluated the prevalence of hypogonadism among men with sexual dysfunction, and examined its association with medical and psychological factors. The study involved 990 men (90% Caucasian) who attended an endocrinology specialist centre for sexual function as a new consultation between July 1995 and July 1997. To identify medical and psychological conditions, patients underwent a detailed clinical evaluation and their medical history was examined. A diagnosis of hypogonadism was made based on a total testosterone level of <300 ng/dL (<10.4 nmol/L) accompanied by three or more signs/symptoms of hypogonadism. Primary hypogonadism was identified when low testosterone levels were accompanied by normal levels of luteinizing hormone (≥9 IU/L). Associations between conditions (medical and psychological) and hypogonadism were examined using the Mantel−Haenszel-test.

The mean age of the men was 57.4 years and all had sexual dysfunction. Overall, 359 men (36.3%) had hypogonadism, most of whom were diagnosed with secondary hypogonadism (301 men). The men in this study had a high prevalence of chronic medical and/or psychological conditions, including; diabetes mellitus (23.1%), hypertension (35.8%), atherosclerotic coronary artery disease (19.9%), work-related stress (27.5%) and anxiety/depression (21.0%), and 28.2% of men were on multiple medications.

In a retrospective observational cohort study testosterone therapy was associated with decreased mortality in men with low testosterone levels compared with no testosterone treatment

menshealthcare@bayerhealthcare.com — Wed, 08 Aug 2012 19:00:00 +0100

This observational, retrospective cohort study based on a clinical database that included seven Veteran Affairs medical centres in the US was the first to examine the association between testosterone treatment and mortality in men with low testosterone levels. Mortality was compared in testosterone-treated compared with untreated hypogonadal men, using appropriate statistical models adjusted for age, diabetes and coronary heart disease. Testosterone formulations included intramuscular injections (88.6%), patch (9.1%) or gel (2.3%). The cohort included 1031 men aged >40 (mean 62) years with low total testosterone levels ≤8.7 nmol/L (250 ng/dL) at study entry, no history of prostate cancer, who were assessed in 2001–2002 and followed-up until the end of 2005 (mean follow-up time 40.5 months).

Read more

Effects of long-acting testosterone undecanoate on health-related quality of life in hypogonadal men: results of a randomized, double-blind study

menshealthcare@bayerhealthcare.com — Wed, 25 Jul 2012 18:30:00 +0100

This randomized, double-blind, placebo-controlled study evaluated the effect of long-acting testosterone treatment in Malaysian men with low testosterone levels, assessing treatment effects using the Aging Male Symptoms (AMS) scale. The participants in this single-centre study were aged 40−70 years and had at least mild symptoms on all three AMS scale subdomains (somatovegetative domain score ≥9, psychological domain score ≥6, sexual domain score ≥6) or total AMS score ≥27, and an early morning total testosterone level of ≤12 nmol/L (346 ng/dL). Participants were randomized 1:1 to receive long-acting injectable testosterone undecanoate 1000 mg (n=60) or placebo injection in an identical form (n=60) at weeks 0, 6, 18, 30 and 42 after formal enrolment. Participants were assessed at baseline and at 18 and 48 weeks after initial intramuscular injection, and the effects of treatment were assessed using repeated measure ANOVA. At baseline the mean total AMS score was 38.46±11.85 for the placebo group and 41.73±12.73 for the treatment group.

Read more

Examining the role of testosterone in the etiology and treatment of obesity, the metabolic syndrome and diabetes in hypogonadal men

menshealthcare@bayerhealthcare.com — Mon, 21 May 2012 09:00:00 +0100

The review looks beyond the role of testosterone in the male reproductive system and sexual functioning to consider its significance in the development and treatment of obesity, a condition that is acknowledged to be reaching global epidemic proportions. The role of testosterone in glucose homeostasis, lipid metabolism and cardiovascular (CV) pathology is examined, and the implications of low testosterone levels on morbidity and mortality are discussed. The article outlines evidence for the effects of normalizing testosterone levels on insulin sensitivity, visceral adiposity and lipid profiles, and addresses the safety of testosterone, particularly in elderly men.

Rational approach to categorizing testosterone levels using community-based reference ranges

menshealthcare@bayerhealthcare.com — Wed, 02 May 2012 09:00:00 +0100

This study generated reference limits for total and free testosterone levels in a community-based sample of nonobese healthy young (19-40 years) men enrolled in the Framingham Heart Study third generation cohort. These reference limits were then applied to three geographically distinct cohorts of community dwelling men drawn from the Framingham Heart Study (FHS) generations 2 and 3, the European Male Aging Study (EMAS) and the Osteoporotic Fractures in Men Study (MrOS). A ‘gold standard’ assay method, liquid chromatography tandem mass spectrometry (LC-MS/MS) was used throughout to determine total testosterone levels; free testosterone levels were calculated using a published law-of-mass-action equation.
Researchers then investigated whether men deemed to have low total and free testosterone levels by the proposed reference limits had a higher prevalence of physical dysfunction, sexual symptoms, and diabetes mellitus, the three categories of conditions most consistently associated with low testosterone levels. Physical function measures (including low walking speed, difficulty climbing stairs, self-reported mobility limitation and frailty) and diabetes were investigated in all three cohorts; sexual symptoms (including decreased morning erections, erectile dysfunction and decreased frequency of sexual thoughts) were available only in EMAS.

Time-course of biological effects of testosterone replacement therapy

menshealthcare@bayerhealthcare.com — Mon, 16 Apr 2012 09:00:00 +0100

This article reviewed the published literature of studies analyzing the effects of testosterone administration in hypogonadal men to estimate the onset or time-dependency effects of testosterone. The analysis consisted of studies performed with testosterone (including testosterone esters and dihydrotestosterone preparations, independent of delivery method) where:

the use of an active treatment group was compared with a matched placebo or control group
a description of the time course of the effect of active treatment was included, and
randomization, adherence to protocol and single/double-blind study design was reported.

Only full articles published in peer-reviewed medical journals were included.

Current knowledge on testosterone deficiency with practical recommendations for diagnosis and treatment

menshealthcare@bayerhealthcare.com — Mon, 02 Apr 2012 09:00:00 +0100

This article aimed to provide practical recommendations for the diagnosis of testosterone deficiency (TD) and information on the benefits and risks of testosterone replacement in middle-aged and older men through a comprehensive review of epidemiological and clinical studies. The review addressed the potential role of testosterone in general men’s health concerns, including the sexual realm, metabolic effects, body composition and mortality, and included an analysis of treatment modalities and examination of current areas of concern and uncertainty.

Read more

Data strongly suggests a relationship between testosterone deficiency and frailty in elderly men

menshealthcare@bayerhealthcare.com — Thu, 08 Mar 2012 09:00:00 +0100

This review aimed to discuss the relationship between low testosterone level and frailty in elderly men and to evaluate the data which show that treatment of frail hypgonadal men with testosterone replacement therapy (TRT) improves physical functioning and reduces some common risk factors for cardiovascular disease.

Read more

Long-acting testosterone undecanoate (TU) injection, but not oral TU, improves metabolic parameters in hypogonadal men

menshealthcare@bayerhealthcare.com — Thu, 01 Dec 2011 09:00:00 +0100

This randomized, double-blind, double-dummy study was the first clinical trial to compare the efficacy and safety of long-term testosterone replacement therapy using two different preparations of testosterone undecanoate (TU), in hypogonadal men with metabolic syndrome (MetS) and/or type 2 diabetes mellitus (T2DM). Patients were randomized to one of three parallel treatment arms; oral TU (80 mg twice daily), intramuscular (IM) TU (1000 mg initially, then repeated every 12 weeks from week 6) or transdermal placebo gel (3–4 g/day). After 6 months, the oral testosterone group was crossed over to receive IM TU for 6 months; the other groups continued with their initial treatment for a further 6 months.

Read more

Endocrine aspects of the diagnosis and treatment of male sexual dysfunction: new ISSM Guidelines

menshealthcare@bayerhealthcare.com — Thu, 01 Sep 2011 19:00:00 +0100

This article is a summary of the report by the Endocrine Aspects of Male Sexual Dysfunctions international experts Committee aimed to provide guidelines based on best evidence for the diagnosis and treatment of endocrine-related male sexual dysfunction. It was prepared in collaboration with the Standards Committee of the International Society of Sexual Medicine (ISSM) and presented at the Third International Consultation of Sexual Medicine (ICSM) in Paris in July 2009. The report was finalized following detailed review of the medical literature, extensive discussion over two years, and public presentation and discussion with other experts, and provides a standardized process for the diagnosis and treatment of endocrine-related male sexual dysfunction. A total of 30 evidence-based recommendations were made and the supporting evidence detailed, including updated knowledge on the prostate and cardiovascular safety of testosterone; key recommendations are presented in this article.

Testosterone undecanoate injection normalizes testosterone levels and improves sexual function in Korean men with hypogonadism and ED

menshealthcare@bayerhealthcare.com — Tue, 28 Jun 2011 19:00:00 +0100

This prospective, multicentre study assessed the efficacy and safety of testosterone replacement therapy (TRT) with a long-acting intramuscular injection of testosterone undecanoate (Nebido®) in an Asian population.1 A total of 133 Korean patients (mean age 54, range 42–75 years) with erectile dysfunction (ED) and testosterone deficiency syndrome (serum testosterone <3.5 ng/mL [12 nmol/L]) were treated with testosterone undecanoate 1000 mg at baseline and again at 6 and 18 weeks. The primary efficacy endpoints were the changes in International Index of Erectile Function (IIEF) score from the initial visit to the final visit (24 weeks) and from the initial visit to each visit. Changes in the Aging Males' Symptoms (AMS) Scale and the Global Efficacy Question (GEQ) for improvement of erectile function were also evaluated.

Evidence-based criteria identifying late-onset hypogonadism defined

menshealthcare@bayerhealthcare.com — Wed, 08 Jun 2011 19:00:00 +0100

This was a systematic investigation of a random population sample of 3369 middle-aged and elderly men (aged 40–79 years) to establish evidence-based criteria for identifying late-onset hypogonadism in the general population on the basis of an association between symptoms and a low testosterone level. The men surveyed were participating in the European Male Aging Study (EMAS) at eight European centers. Data were collected on the men’s general, sexual, physical, and psychological health, and total testosterone levels were measured in morning blood samples and free testosterone levels were calculated. Data were randomly split into separate training and validation sets for confirmatory analyses.

A total of 32 items were considered as possible candidates for symptoms of androgen deficiency on the basis of previous recommendations and studies; all items were then screened statistically and those that were significantly associated with total or free testosterone levels were selected for independent validation and further divided into symptomatic and asymptomatic categories. The findings were published in the New England Journal of Medicine.

The addition of testosterone therapy improves erectile function in hypogonadal men who fail to respond to phosphodiesterase type 5 inhibitor (PDE5-I) therapy alone

menshealthcare@bayerhealthcare.com — Fri, 20 May 2011 19:00:00 +0100

This study aimed to confirm that testosterone replacement therapy (Testogel^®, Androgel^®) improved erectile function in men with erectile dysfunction (ED) who were nonresponders to phosphodiesterase type 5 inhibitors (PDE5-Is). The study also investigated the impact of baseline testosterone levels on response to treatment. The multicentre, multinational, double-blind, placebo-controlled study (TADTEST) included 173 men (age 45–80 years) with baseline total testosterone levels ≤400 ng/dL or bioavailable testosterone ≤100 ng/dL and inadequate response to 4 weeks of treatment with the PDE5-I tadalafil (Cialis^®) 10 mg once a day. Once-daily tadalafil treatment was continued for an additional 12 weeks and men were randomized also to receive placebo or testosterone 50 mg once daily in the form of a 1% hydro-alcoholic gel, to be increased to 100 mg if results were unsatisfactory. The Erectile Function Domain (EFD) Score of the International Index of Erectile Function (IIEF) and rate of successful intercourse attempts were the main outcomes measured.

Meta-analysis supports association between metabolic syndrome and hypogonadism; testosterone replacement therapy may improve metabolic control and reduce central obesity

menshealthcare@bayerhealthcare.com — Thu, 05 May 2011 19:00:00 +0100

A systematic review and meta-analysis of available prospective and cross-sectional studies comparing androgen levels in men with or without metabolic syndrome (MetS) was performed to analyse the relationship between androgen levels and MetS.1 Additionally, a separate meta-analysis of available randomized controlled trials reporting the metabolic effects of testosterone replacement therapy was performed. Overall, 21 quality studies were included; 13 cross-sectional, 3 longitudinal and 4 randomized controlled published trials, and 1 unpublished randomized controlled trial. Data for 2,254 men with and 6,407 men without MetS were included.

Testosterone replacement therapy improves body composition, insulin resistance and markers of atherosclerosis in men with low testosterone and metabolic syndrome

menshealthcare@bayerhealthcare.com — Thu, 21 Apr 2011 17:00:00 +0100

The aim of this study was to evaluate whether long-term testosterone replacement therapy could modify cardiovascular risk factors and atherosclerosis progression in a population of hypogonadal men with metabolic syndrome (MetS) and/or type 2 diabetes mellitus (T2DM). The randomized, double-blind, double-dummy, placebo-controlled, parallel group study enrolled 50 men (mean age 57 years) to receive intramuscular (IM) testosterone undecanoate (TU) 1000 mg every 12 weeks (n=40) or placebo transdermal gel (3-6 g daily; n=10) for 24 months. Hypogonadism was defined as total testosterone ≤11 nmol/L or free testosterone ≤250 pmol/L; MetS and T2DM were defined according to National Cholesterol Education Program-Third Adult Treatment Panel (NCEP-ATPIII) and International Diabetes Federation (IDF) criteria.

Testosterone deficiency – data available from RHYME study in 2013

menshealthcare@bayerhealthcare.com — Fri, 15 Apr 2011 17:00:00 +0100

The natural history of testosterone deficiency in men and outcomes associated with testosterone therapy: a multi-national patient registry. RC Rosen, AB Araujo, AB O'Donnell, JB McKinlay. New England Research Institutes, Watertown, MA, USA.

Despite testosterone (T) therapy being used to treat testosterone deficiency for approximately 70 years, no large scale, long term study has fully addressed the natural history of testosterone deficiency or the long term safety of testosterone treatment.

In May 2009 it was announced that a Registry of HYpogonadism in MEn (RHYME) would be established to maintain a multi-national (European) data-set of around 1,000 patients (aged 18 and over), drawn from some 20 clinical sites, diagnosed with late-onset hypogonadism (HG), hypogonadism secondary to medical illness, and classical hypogonadism (eg, Klinefelter's syndrome).1,2 Men registered on RHYME are not required to undergo T treatment for diagnosed HG.

The primary goal of RHYME is to examine the association between testosterone therapy and prostate health (eg, rate of positive prostate biopsies (primary endpoint), incidence of prostate cancer and Benign Prostatic Hyperplasia) of men with HG that some believe is put at risk by testosterone therapy. Other goals include the assessment of HG symptoms and general health outcomes in men with HG treated with T, as well as their clinical course compared to those men with HG who are not treated.

The Registry will draw on observational studies at baseline, three months, and then yearly intervals (for a minimum of two years). Data collected will include a full medical history, a physical examination, blood sampling, and patient questionnaires.

Men with erectile dysfunction and low testosterone levels have an increased risk of dying from cardiovascular disease

menshealthcare@bayerhealthcare.com — Fri, 01 Apr 2011 18:55:00 +0100

A consecutive series of 1687 patients attending an andrology clinic for erectile dysfunction (ED) was followed for a mean of 4.3 ± 2.6 years to investigate whether low testosterone levels predict incident fatal or nonfatal major adverse cardiovascular events (MACE) in men with ED. Patients in this prospective cohort study were interviewed using the structured interview on erectile dysfunction (SIEDY) and the ANDROTEST structured interview to measure aspects of ED and hypogonadal-related symptoms. Total testosterone was evaluated at baseline and information on MACE was obtained from registry database records.

Read more

Low testosterone is common in men with coronary heart disease and negatively impacts survival

menshealthcare@bayerhealthcare.com — Fri, 11 Mar 2011 18:55:00 +0100

A total of 930 men (mean age 61 years) were followed in a prospective cohort study for a mean of 6.9 years to determine the prevalence of testosterone deficiency and to investigate the effect of serum testosterone levels on survival in men with confirmed coronary disease.1 The cohort was a consecutive series of men referred to a tertiary cardiothoracic centre for diagnostic coronary angiography between June 2000 and June 2002. Significant coronary artery disease was defined as 70% or greater stenosis in any epicardial coronary artery or 50% or greater stenosis of the main stem of the left coronary artery.

Read more

Study shows testosterone (T) improves body composition and hip bone mineral density in elderly men with low T

menshealthcare@bayerhealthcare.com — Tue, 22 Feb 2011 14:00:00 +0100

Testosterone treatment in elderly men with subnormal testosterone levels improves body composition and BMD in the hip. J Svartberg, I Agledahl, Y Figenschau, T Sildnes, K Waterloo and R Jorde. International Journal of Impotence Research. 2008:20;378–387.

Researchers examined whether lower than normal T levels in elderly men were associated with a reduced quality of life (QoL), as well as physical and mental health, and whether T treatment could improve these conditions.

Read more

Testosterone with diet and exercise reverses Metabolic Syndrome and improves glycemic control in hypogonadal men with newly diagnosed Type 2 Diabetes

menshealthcare@bayerhealthcare.com — Wed, 19 Jan 2011 20:00:00 +0100

In a single blind 52-week randomized clinical trial, 32 hypogonadal men (morning plasma testosterone concentration lower than 12 nmol/L, reference range >14 nmo/l) with recently diagnosed Type 2 Diabetes (T2D) and with Metabolic Syndrome (MetS) underwent supervised diet and exercise (D&E). Half of this group received D&E with testosterone administered as a relatively low dose (50 mg) gel (Testogel®) once daily. No glucose-lowering agents were administered prior to or during the study period.

Read more

Largest international trial indicates that testosterone replacement therapy is an effective and well tolerated treatment for male hypogonadism

menshealthcare@bayerhealthcare.com — Wed, 08 Dec 2010 17:00:00 +0100

Systematic reviews of randomized, placebo-controlled clinical trials of testosterone in men, including older men (aged 60 years and over) and middle-aged men, with sexual dysfunction and hypogonadism have shown large favourable effects on libido, but moderate effects on satisfaction with erectile function.

Outcomes in clinical trials of the effect of testosterone treatment on mood have varied. However, there has been evidence that testosterone treatment results in improvements in mood, particularly in older men with hypogonadism.

The benefits of testosterone treatment on body composition have consistently been demonstrated in clinical studies of testosterone therapy in hypogonadal men or men with borderline low testosterone levels.

Read more

Exercise performance in men with stable angina improved by testosterone over 12 month period

menshealthcare@bayerhealthcare.com — Wed, 24 Nov 2010 14:15:00 +0100

This was a double-blind, randomised, parallel group placebo-controlled trial involving a single centre study that investigated 13 (originally 15) hypogonadal men (mean T was 9.9nmol/l1) with stable angina on optimal anginal treatment randomised to Nebido 1000mg/3 months or placebo. Exercise (treadmill) testing was conducted at 3, 6, and 12 months after baseline tests along with metabolic parameters.

This was the first 12 months outcome study showing a sustained effect on time to ST depression.

There were no adverse effects.

Testosterone improves depression and quality of life scores in hypogonadal men

menshealthcare@bayerhealthcare.com — Fri, 15 Oct 2010 14:18:00 +0100

The Russian study looked at 184 men with metabolic syndrome (Met S) and hypogonadism. This was a double-blind, placebo-controlled study of Nebido 1000mg vs placebo. The baseline testosterone (T) for this 30 week study was 8.0 nmol/l. The mean baseline BMI was 35.5 kg/m21 with a reduction of 1.32 occuring in the treatment group and no change with placebo.

The baseline BDI depression score improved by 2.5 (p=0.003), AMS scale by 7.4 (p<0.001) and IIEF-5 by 3.1 (P<0.001). The strongest effect was seen in men with lowest baseline T levels.

Testogel® reduces fat and improves body composition and quality of life scores

menshealthcare@bayerhealthcare.com — Thu, 23 Sep 2010 13:00:00 +0100

This multi-centre, double-blind placebo-controlled study assessed the efficacy and safety of Testogel® (1% testosterone gel) in 352 men aged 50-80 years with late-onset hypogonadism.

The primary outcome measure was change from baseline to 6 months in lean body mass (assessed using dual-energy X-ray absorptiometry). Fat mass, total body mass, health-related quality of life (assessed using the Aging Males’ Symptoms Scale [AMS]) and serum lipid levels were also assessed.

The increase in lean body mass was significantly greater with testosterone than placebo (Figure). This increase occurred irrespective of age and baseline serum total testosterone levels. Fat mass decreased by 1.13 kg with testosterone and 0.09 kg with placebo (Figure). No significant changes in total body mass were observed with either testosterone or placebo. Significant improvements in quality of life scores were observed with testosterone (-10.8) compared with placebo (-6.9; p<0.05). Improvements in lipid parameters were also noted. No unexpected safety concerns arose during the study.

Change in lean body mass and fat mass with testosterone and placebo. *p<0.0001 versus placebo.

Read more

Testosterone improves functional performance in elderly men with chronic heart failure

menshealthcare@bayerhealthcare.com — Tue, 17 Aug 2010 02:00:00 +0100

This 12-week, double-blind, placebo-controlled, randomised study evaluated the effect of long-acting testosterone treatment in elderly men with stable chronic heart failure (CHF). Seventy patients (median age 70 years) were recruited and randomised 1:1 to receive intramuscular Nebido or intramuscular saline at 6 week intervals. The baseline characteristics of testosterone and placebo groups were well balanced, and approximately one-third of patients in each group had hypogonadism. The study found that 12 weeks of testosterone treatment provided significant improvements from baseline in skeletal muscle function, cardiorespiratory indices and insulin resistance (HOMA-IR) that were not seen in the placebo group (Table). Furthermore, the improvements in VO2 (a measure of physical fitness) and MVC (a measure of skeletal muscle strength) were dose-dependent, i.e. the higher the change in testosterone levels, the greater the improvement. Patients were already on comprehensive therapy for heart failure, and testosterone treatment was well tolerated in these frail patients, many of whom were on multiple concomitant medications.

Read more

Testosterone reduces visceral fat and increases muscle mass in non-obese men aged ≥ 55 years

menshealthcare@bayerhealthcare.com — Wed, 04 Aug 2010 21:00:00 +0100

This Australian, double-blind, placebo-controlled 12-month study assessed the effect of the testosterone patch on total and regional body composition (using dual-energy X-ray absorptiometry and magnetic resonance imaging) and hormonal and metabolic indices in 60 healthy but symptomatic non-obese males aged ≥55 years with total testosterone <15 nmol/L.

Testosterone levels increased by 30% with testosterone (p<0.05) and fell by 10% with placebo (p<0.05). Bodyweight, body mass index and waist circumference did not change during treatment. Fat-free mass increased with testosterone and was unchanged with placebo (Figure); skeletal muscle mass followed the same trend (p=0.008). No changes in total body fat mass, regional fat mass, percentage body fat or abdominal subcutaneous fat were observed. Visceral adipose tissue mass decreased with testosterone and increased with placebo (p=0.001 for testosterone versus placebo); changes in visceral fat correlated with changes in testosterone levels (r2=0.36; p<0.05). A trend towards increased total and low-density lipoprotein cholesterol with placebo was noted.

No significant changes in haematocrit were observed. The dropout rate was high (30%).

Change in fat-free mass with testosterone patch or placebo. *p=0.026 for the between-group differences in change from baseline to 52 weeks.

Read more

Sat, 01 Jan 2000 13:00:00 +0100